Drug Transporter (DT) Information

General Information of DT
DT ID DTD0099
Gene Name SLC15A4
Protein Name Peptide transporter 4
Gene ID
121260
UniProt ID
Q8N697
TCDB ID
2.A.17.3.11
3D Structure

Modelled DT Structure

Method:homology modeling

Template PDB:3F1R_A; 3WIQ_A; 6EI3_A

Identity:63.636%;21.818%;23.952%

Minimized Score:-828.827 kcal/mol

Detail: Structure Info

Synonyms FP12591; PHT1; PTR4; Peptide/histidine transporter 1; SLC15A4; Solute carrier family 15 member 4; hPHT1
DT Family Proton-Dependent Oligopeptide Transporter (POT/PTR) Family ;
Tissue Specificity Highly expressed in skeletal muscle.Moderately expressed in kidney, liver, and heart. Weakly expressedin colon and brain. Expressed in low levels throughout thegastrointestinal tract and in Caco-2 cells. Expressed in retinalfragment epithelium (RPE) and neural retina. Expressed in smallintestine, stomach, duodenum, jejunum, ileum and colon.
Function This proton oligopeptide cotransporter mediates the transport of free histidine and certain di- and tripeptides.
Endogenous Substrate(s) Peptides; Histidine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 4.0)

(α) Tissue Distribution Level of Peptide transporter 4
Tissue Distribution Level (TD)

(β) Cell Distribution Level of Peptide transporter 4
Cell Distribution Level (CD)

(γ) Organelle Distribution Level of Peptide transporter 4
Organelle Distribution Level (Subc)

Regulatory Variability Data of This DT

(β) Post-translational Modification of Peptide transporter 4
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of Peptide transporter 4
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of Peptide transporter 4
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of Peptide transporter 4
Exogenous Modulation (EGM)

Structural Variability Data of This DT

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

General Variability Data of This DT

(α) Genetic Polymorphisms of Peptide transporter 4
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of Peptide transporter 4
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:           1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
L-histidine
 Phase 2/3 Drug Info HARS Syndrome N.A. [1]

Drug-DT Affinity Assessed by Cell Line

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:           3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
L-histidine Phase 2/3 Drug Info Xenopus laevis oocytes-PTR4 Km =16.3 microM [1]
L-histidine Phase 2/3 Drug Info Xenopus laevis oocytes-PTR4 Km =16.3 microM [1]
L-histidine Phase 2/3 Drug Info Xenopus laevis oocytes-PTR4 Km =16.3 microM [1]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:           1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Peptides Investigative Drug Info Xenopus laevis oocytes-PTR4 Km =1.69 microM [1]
References
1 Functional Characterization of Human Peptide/Histidine Transporter 1 in Stably Transfected MDCK Cells. Mol Pharm. 2018 Feb 5;15(2):385-393.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.